Check Out What Whales Are Doing With GILD
Check Out What Whales Are Doing With GILD
Whales with a lot of money to spend have taken a noticeably bullish stance on Gilead Sciences.
資金雄厚的大型鯨魚們明顯對吉利德科學持看好態度。
Looking at options history for Gilead Sciences (NASDAQ:GILD) we detected 9 trades.
我們查看吉利德科學（納斯達克：GILD）的期權歷史後發現了9宗交易。
If we consider the specifics of each trade, it is accurate to state that 44% of the investors opened trades with bullish expectations and 44% with bearish.
如果我們考慮每次交易的具體情況，準確地說，44%的投資者帶着看好的預期開啓了交易，而44%則是看淡的。
From the overall spotted trades, 3 are puts, for a total amount of $108,977 and 6, calls, for a total amount of $345,373.
根據這些交易，共有3個看跌期權，交易總金額爲108,977美元，6個看漲期權，交易總金額爲345,373美元。
What's The Price Target?
目標價是多少？
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $55.0 and $75.0 for Gilead Sciences, spanning the last three months.
通過評估成交量和未平倉合約量，明顯可以看出主力市場關注吉利德科學55.0美元到75.0美元的價格區間，該區間涵蓋過去三個月。
Analyzing Volume & Open Interest
分析成交量和未平倉合約
In today's trading context, the average open interest for options of Gilead Sciences stands at 2975.88, with a total volume reaching 106.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Gilead Sciences, situated within the strike price corridor from $55.0 to $75.0, throughout the last 30 days.
在當今交易背景下，吉利德科學期權的平均未平倉合約爲2975.88，總成交量達到106.00。下面的圖表描繪了吉利德科學高價值交易（期權的看漲和看跌量以及未平倉合約）的進展情況，該區間位於價差走廊的55.0美元至75.0美元，時間跨度爲30天。
Gilead Sciences 30-Day Option Volume & Interest Snapshot
吉利德科學30天期權成交量和未平倉合約快照
Biggest Options Spotted:
最大的期權交易：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GILD | CALL | TRADE | BULLISH | 01/17/25 | $18.2 | $18.2 | $18.2 | $55.00 | $91.0K | 215 | 1 |
| GILD | CALL | TRADE | BEARISH | 06/20/25 | $10.1 | $10.05 | $10.05 | $67.50 | $66.3K | 751 | 0 |
| GILD | PUT | SWEEP | BEARISH | 07/26/24 | $1.04 | $1.0 | $1.0 | $73.00 | $55.9K | 72 | 7 |
| GILD | CALL | SWEEP | BULLISH | 06/20/25 | $10.1 | $9.9 | $10.0 | $67.50 | $54.4K | 751 | 0 |
| GILD | CALL | TRADE | BULLISH | 09/20/24 | $6.4 | $6.3 | $6.38 | $67.50 | $53.5K | 871 | 1 |
| 標的 | 看跌/看漲 | 交易類型 | 情緒 | 到期日 | 賣盤 | 買盤 | 價格 | 執行價格 | 總交易價格 | 未平倉合約數量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GILD | 看漲 | 交易 | 看好 | 01/17/25 | $18.2 | $18.2 | $18.2 | $55.00 | 91000 美元 | 215 | 1 |
| GILD | 看漲 | 交易 | 看淡 | 06/20/25 | $10.1 | $10.05 | $10.05 | $67.50 | 成交量66.3K | 751 | 0 |
| GILD | 看跌 | SWEEP | 看淡 | 07/26/24 | $1.04 | $1.0 | $1.0 | $73.00 | $55.9K | 72 | 7 |
| GILD | 看漲 | SWEEP | 看好 | 06/20/25 | $10.1 | $9.9 | $10.0 | $67.50 | $54.4K | 751 | 0 |
| GILD | 看漲 | 交易 | 看好 | 09/20/24 | 6.4美元 | $6.3 | $6.38 | $67.50 | $53.5K | 871 | 1 |
About Gilead Sciences
關於吉利德科學
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
吉利德科學公司開發和推廣治療威脅生命的傳染病的療法，其核心產品組合主要集中在治療艾滋病毒和乙型及丙型肝炎方面。通過收購 Corus Pharma、Myogen、CV Therapeutics、Arresto Biosciences 和 Calistoga，公司將業務口徑拓展至肺部和心血管疾病以及癌症治療領域。吉利德對 Pharmasset 的收購帶來了治療丙型肝炎藥物 Sovaldi 的權利，這也是組合藥物 Harvoni 的一部分，而 Kite、Forty Seven 和 Immunomedics 的收購則提高了吉利德在細胞治療和非細胞治療腫瘤領域中的曝光度。
In light of the recent options history for Gilead Sciences, it's now appropriate to focus on the company itself. We aim to explore its current performance.
考慮到吉利德科學最近的期權歷史，現在應該關注該公司的表現。我們旨在探索其當前的業績。
Present Market Standing of Gilead Sciences
吉利德科學的目前市場情況
- Currently trading with a volume of 2,761,226, the GILD's price is down by 0.0%, now at $73.51.
- RSI readings suggest the stock is currently may be approaching overbought.
- Anticipated earnings release is in 20 days.
- 目前交易量爲2,761,226的吉利德科學價格下跌了0.0％，現爲73.51美元。
- RSI讀數表明該股目前可能接近超買水平。
- 預計發佈業績還有20天。
What Analysts Are Saying About Gilead Sciences
分析師對吉利德科學的看法
3 market experts have recently issued ratings for this stock, with a consensus target price of $82.33333333333333.
3位市場專家最近對此股票發表了評級，共識目標價爲82.33333333333333美元。
- An analyst from Raymond James upgraded its action to Outperform with a price target of $93.
- Maintaining their stance, an analyst from Baird continues to hold a Neutral rating for Gilead Sciences, targeting a price of $80.
- An analyst from RBC Capital has revised its rating downward to Sector Perform, adjusting the price target to $74.
- 來自雷蒙德詹姆斯的分析師將其評級升級爲增持，並將目標價設定爲93美元。
- 維持他們的立場，來自 Baird 的分析師繼續持有吉利德科學的中立評級，目標價爲 80 美元。
- 來自RBC Capital的分析師已將其評級下調爲板塊內表現，將目標價調整爲74美元。
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Gilead Sciences options trades with real-time alerts from Benzinga Pro.
期權交易存在較高的風險和潛在回報。精明的交易者通過不斷學習、調整策略、監控多種因子並密切關注市場動態來管理這些風險。隨時通過Benzinga Pro獲得有關吉利德科學期權交易的實時提醒，以保持了解最新情況。